Your health insurance premiums may take a big jump in 2027 — here's why

U.S. employer health-benefit costs are projected to rise 8.2% to 11.1% per worker in 2027, the largest increases in more than two decades, with employers likely to shift costs to workers through higher premiums, deductibles and copays. ACA marketplace insurers have proposed a median 15% premium increase for 2027, following a 20% finalized increase in 2026; unsubsidized enrollees face premiums 30% to 40% higher over two years. GLP-1 utilization alone is estimated to add 1 percentage point to employer cost growth, while inflation, healthcare labor shortages, provider consolidation and the expiry of enhanced ACA subsidies are also driving costs higher. Rising affordability pressures could become a material issue in the midterm and 2028 elections.

Analysis

The investable read-through is not broad managed-care upside: employer self-insurance means much of the near-term medical-cost shock is retained by corporate plan sponsors, while insurers primarily earn administrative fees. The cleaner beneficiaries are benefits consultants WTW and Marsh McLennan (MMC; "MRSH" is not the listed equity ticker), as renewal repricing, plan redesign, pharmacy-benefit audits and GLP-1 utilization controls increase consulting demand. Their revenue upside is likely modest but high-margin and visible over the next 1-3 renewal cycles; this supports multiple resilience rather than a step-change in earnings.

The more consequential second-order effect is a consumer demand drag. Higher payroll deductions and deductible exposure are a recurring reduction in disposable income, disproportionately affecting middle-income households with employer coverage and unsubsidized individual-market participants. Over 6-18 months, this favors defensive consumer staples and off-price retail over discretionary categories with high ticket sizes; it is incrementally negative for restaurants, apparel and travel if employers shift a material portion of cost increases to employees.

GLP-1 cost containment is a two-sided catalyst. Restrictions on weight-loss coverage would pressure volume expectations for Novo Nordisk (NVO) and Eli Lilly (LLY) at the employer-plan margin, but the more likely response is prior authorization, step therapy and tighter persistence management rather than outright exclusion. Consensus may overestimate the immediate payer backlash: reduced cardiometabolic claims accrue over years, while pharmacy expense is immediate, making 2027 formulary decisions a near-term earnings-risk variable even if long-run clinical economics remain favorable.

The policy tail risk is an adverse-selection spiral in individual coverage: healthier members exiting raises future claims intensity and forces successive repricing. A legislative restoration of enhanced subsidies, especially following election-driven affordability pressure, would reverse that mechanism quickly and benefit ACA-exposed insurers such as CVS/Aetna, Centene (CNC) and Elevance (ELV); absent verified enrollment deterioration or revised insurer guidance, this remains a watch item rather than a directional insurer trade.

Key Decisions for Investors

• Accumulate WTW and MMC on market weakness through the next two quarterly results; use a 6-12 month horizon for renewal-cycle consulting and brokerage revenue. Thesis is invalidated if organic growth or operating-margin guidance fails to improve despite elevated benefit-cost inflation; favor WTW if valuation is at a meaningful discount to MMC.
• Initiate a 3-6 month defensive consumer pair: long XLP or COST / short XLY, sized modestly. The mechanism is recurring healthcare cost pass-through reducing discretionary wallet share; exit if real wage growth reaccelerates or retailers report no increase in consumer credit stress.
• Do not chase a broad long in ELV, CNC or CVS solely on premium repricing. Set alerts for ACA enrollment attrition, state rate approvals, and 2027 medical-loss-ratio guidance; long exposure is warranted only if approved rates exceed cost trend without membership deterioration.
• For GLP-1 exposure, retain core LLY/NVO positions but hedge event risk around large employer formulary announcements with limited-risk 3-6 month puts or a partial LLY/NVO versus XLV pair reduction. Falsification of the bearish hedge is evidence that covered lives and refill persistence remain stable despite utilization-management changes.